Vanda Pharmaceuticals secures orphan drug designation in Japan for Imsidolimab in generalized pustular psoriasis

Vanda Pharmaceuticals secures orphan drug designation in Japan for Imsidolimab in generalized pustular psoriasis
Vanda Pharma wins orphan drug status

Vanda Pharmaceuticals has announced that Japanese regulators have granted orphan drug designation to its investigational therapy Imsidolimab for the treatment of generalized pustular psoriasis.

This recognition is expected to support the company’s efforts to bring Imsidolimab to patients with this rare and serious skin disorder in Japan, facilitating an accelerated development and approval process. Orphan drug status typically provides benefits such as market exclusivity and potential regulatory and financial incentives.

Vanda Pharmaceuticals continues to develop and expand its portfolio of specialty treatments. Earlier this year, the company announced that NEREUS (tradipitant) is now available for direct consumer orders in the U.S.. The launch reflects Vanda's ongoing efforts to increase access to novel therapies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.